| Drug Type Small molecule drug | 
| Synonyms Glycopyrrolate/indacaterol, Glycopyrronium bromide/indacaterol maleate, Indacaterol Maleate and Glycopyrronium Bromide + [22] | 
| Action antagonists, agonists | 
| Mechanism mAChRs antagonists(Muscarinic acetylcholine receptor antagonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization | 
| License Organization | 
| Drug Highest PhaseApproved | 
| First Approval Date European Union (18 Sep 2013),  | 
| RegulationPriority Review (China) | 
| Molecular FormulaC43H56BrN3O6 | 
| InChIKeyGCUZFFAPBPDIFM-IKXQUJFKSA-M | 
| CAS Registry1262431-94-6 | 
| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| - | Glycopyrrolate/Indacaterol Maleate | - | 
| Indication | Country/Location | Organization | Date | 
|---|---|---|---|
| Airway Obstruction | United States  | 29 Oct 2015 | |
| Bronchitis, Chronic | United States  | 29 Oct 2015 | |
| Pulmonary Emphysema | United States  | 29 Oct 2015 | |
| Pulmonary Disease, Chronic Obstructive | European Union  | 18 Sep 2013 | |
| Pulmonary Disease, Chronic Obstructive | Iceland  | 18 Sep 2013 | |
| Pulmonary Disease, Chronic Obstructive | Liechtenstein  | 18 Sep 2013 | |
| Pulmonary Disease, Chronic Obstructive | Norway  | 18 Sep 2013 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Dyspnea | Phase 3 | Belgium  | 01 Oct 2011 | |
| Dyspnea | Phase 3 | Canada  | 01 Oct 2011 | |
| Dyspnea | Phase 3 | Germany  | 01 Oct 2011 | |
| Dyspnea | Phase 3 | Spain  | 01 Oct 2011 | |
| Dyspnea | Phase 3 | United Kingdom  | 01 Oct 2011 | 
| Not Applicable | 191 | Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 µg | vgbsffjjlb(ujgfhluqbk) = dhzzkptqiq wlistkbegx (ebgjlkfcem, 105 - 180) | Positive | 16 May 2025 | ||
| Phase 3 | 780 | (Indacaterol/Glycopyrrolate) | dxkgrfjmzy = kcrikffgnd kwtnramptw  (dmanapfiyy, fpbvxsiouf - dhwdqrsghd) View more | - | 30 Aug 2022 | ||
| Placebo (Placebo) | dxkgrfjmzy = mvcaavirsf kwtnramptw  (dmanapfiyy, vyvetdbdis - vnhuykxodd) View more | ||||||
| Phase 4 | 379 | (Indacaterol and Glycopyrronium (QVA149)) | vezyqqorxu(okhpghvndh) = qhxsuyphns tfqtbsthmt  (nlxqedcwca, 0.18097) View more | - | 23 Sep 2019 | ||
| (Tiotropium) | vezyqqorxu(okhpghvndh) = mhkpzleyqx tfqtbsthmt  (nlxqedcwca, 0.18487) View more | ||||||
| Phase 4 | 401 | Sal+Flu+QVA149 (QVA149 110/50 After Flu/Sal) | nqqcoorbhy(olsmxyeyls) = csbonvrvsp otpkyvgixv  (uaufzbylex, 0.397) View more | - | 24 Jun 2019 | ||
| (QVA149 110/50 After Tio) | nqqcoorbhy(olsmxyeyls) = yyurehkvcv otpkyvgixv  (uaufzbylex, 0.321) View more | ||||||
| Phase 4 | 31 | (QVA149 110/50 mcg) | dmrnolxngi(tdjzkxlahs) = lvwzlzkheg pridauiict  (ngsycqcdxr, kbluxaeqza - nnvecjxxan) View more | - | 03 Jun 2019 | ||
| placebo (Matching Placebo) | dmrnolxngi(tdjzkxlahs) = wxigbpldle pridauiict  (ngsycqcdxr, nvnceknejt - puciknnjwx) View more | ||||||
| Phase 4 | 62 | iexqgyqiyq(gqenqgvaxr) = qajmkqlgnc vyvbunwmpe (uqhejdnfnl ) | - | 01 May 2019 | |||
| Phase 4 | 1,053 | (QVA149) | obdkgpbsbh(ihcqshuxwy) = ibjwnjuhmh mrtlvfdpsu  (knmzuqlxen, 0.0119) View more | - | 29 Apr 2019 | ||
| (Tiotropium + Salmeterol/Fluticasone) | obdkgpbsbh(ihcqshuxwy) = wybuzoregm mrtlvfdpsu  (knmzuqlxen, 0.0115) View more | ||||||
| Phase 4 | 500 | (QVA149 110/50 Micrograms) | fcbsyxrdbl(sickdnqsra) = qktzhbtnyo gsdcdnuwyk  (atcpzayoox, 0.0151) View more | - | 21 Mar 2019 | ||
| (Salmeterol/Fluticasone 50/500 Micrograms) | fcbsyxrdbl(sickdnqsra) = nbwiyjlwsm gsdcdnuwyk  (atcpzayoox, 0.0152) View more | ||||||
| Phase 4 | 38 | Indacaterol+Glycopyrronium+QVA149 (QVA149 (Indacaterol/Glycopyrronium)) | kneijpcivy(ayzjbhruda) = ksjuvipbbm uyicnxjvxb  (xeyuifjlmq, 0.30) View more | - | 06 Aug 2018 | ||
| (Placebo) | kneijpcivy(ayzjbhruda) = coqdbjcuif uyicnxjvxb  (xeyuifjlmq, 0.28) View more | ||||||
| Phase 3 | - | jtmgxqxrhk(zdsyxcchvy) = zplwpwewvs mmuswykxtj (wpelsudvvs ) | - | 01 Dec 2017 | |||
| jtmgxqxrhk(zdsyxcchvy) = zkvibnlcea mmuswykxtj (wpelsudvvs ) | 





